Related Tags

Awaiting JNC-8, Revised Classification of Hypertension Offers Practical Pointers

Awaiting JNC-8, Revised Classification of Hypertension Offers Practical Pointers 


By Laura Brasseur


In anticipation of JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), the hypertension writing group (HWG), which offered a new definition of hypertension during the annual meeting of the American Society of Hypertension (ASH) and was discussed in this journal in July 2005, have now published the details of their new classification in the Journal of Clinical Hypertension (2005;7:505-512), refocusing their treatment goals.  


“Our classification amplifies the JNC 7 definition [Table 1],” write Thomas D. Giles, MD, president of ASH, and colleagues. “We afford even greater priority to risk factors and early markers of cardiovascular disease, target organ damage, and overt cardiovascular disease than to observed blood pressure patterns” (Table 2).


The HWG describes previously published blood pressure (BP) cut points as “a moving target,” tracing the history of the diagnostic criteria for hypertension from a pre-1984 diastolic BP of >105 mm Hg to the latest JNC 7 publication, which introduced the category of “prehypertension.”


HWG quarrels with the idea of “assigning an illness diagnosis” (ie, prehypertension) to persons who, although they have a BP level of 120-140/80-90 mm Hg, may actually be at low risk for cardiovascular disease (CVD). They advocate instead the “normal” and “hypertensive” categories based on patients’ cardiovascular (CV) risk profile.


Because risk factors for early CVD can exist before any predefined BP threshold has been crossed, they stress the following CV risk factors:

·Increasing age

·BP ³140/90 mm Hg

·Overweight/obesity (body mass index ³24)

·Abdominal obesity (waist circumference >40 in for men and >35 in for women)

·Dyslipidemia: low-density lipoprotein cholesterol ³130 mg/dL; high-density

   lipoprotein cholesterol <40 mg/dL for men and <50 mg/dL for women; triglycerides

   ³150 mg/dL

·Fasting blood glucose ³100 mg/dL, insulin resistance, or diabetes


·Family history of CVD at age <50 years in men or <60 years in women

·Sedentary lifestyle

·Elevated high-sensitivity C-reactive protein.


Physicians should also evaluate for early markers of CVD, including BP-related markers (ie, loss of nocturnal BP dipping, exaggerated BP response to exercise, salt sensitivity, and widened pulse pressure). Other early disease markers include physiologic alterations in the cardiac (eg, mild left ventricular hypertrophy), vascular (eg, coronary calcification), and renal (eg, microalbuminuria) systems, and hypertensive retinal changes.


“Defining hypertension as a complex cardiovascular disorder associated with, but not exclusively defined by, high BP levels is a transitional strategy that is intended to pave the way for further research and clinical investigations aimed at detecting and treating disease at an earlier phase,” the authors conclude.


Table 1. BP cut point classification: JNC 7 vs HWG


SBP, mm Hg   DBP, mm Hg  JNC 7                          HWG

<120                <80                  Normal                                    Normal

120-140           80-90               Prehypertension                       Normal or stage 1

140-160           90-100             Stage 1                         Stage 1 or stage 2

>160                >100                Stage 2                         Stage 3


HWG = Hypertension Writing Group; SBP = systolic blood pressure; DBP = diastolic blood pressure.



Table 2. The new classification of hypertension


                                                            CV risk           Early CV        Target-organ

Classification  BP and CVD                  factors            markers         disease

Normal                        Normal BP or rare BP  None                None                None


                        No identifiable CVD


Stage 1             Occasional/intermittent            ³1                    0-1                   None

hypertension    BP elevations


                        Risk factors/markers

                        suggesting early CVD


Stage 2             Sustained BP elevation            Multiple           ³2                    Early signs

hypertension    or

                        Evidence of

                        progressive CVD


Stage 3             Marked and sustained  Multiple           ³2 with            Overt, with or

hypertension    BP elevations                                       evidence of      without CV events

                        or                                                         CVD               

                        Evidence of advanced



CV = cardiovascular; BP = blood pressure; CVD = cardiovascular disease.

Most Popular

Recommended Reading

Several trials have been conducted, and many more are yet to be completed, that have the goal of addressing whether intensive blood glucose control and intensive blood pressure (BP) control have any long-term benefit on all-cause mortality and major cardiovascular events. Contradictory data have been published with respect to the short- and long-term benefits of aggressive BP and blood glucose control versus conventional treatments for BP and glucose control. This review presents the main points of some of the important trials to date on this subject.
Air pollution should be viewed as one of several major modifiable risk factors in the prevention and management of cardiovascular disease.
Isolated systolic hypertension (ISH) in young and middle-aged adults is on the rise. A study in the Journal of the American College of Cardiology found that ISH puts these patients at higher relative risk for heart disease and mortality than their peers with normal blood pressure. That raises the question of whether these younger ISH patients should be getting drug therapy.
The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).